Doxorubicin Hydrochloride Injection, Suspension, Liposomal
Product Images NDC 68001-629

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Doxorubicin Hydrochloride (NDC 68001-629). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Doxorubicin Hydrochloride (1a930cb7 5363 4229 9f39 53edc07a43d6 01)

Chemical structure of Doxorubicin Hydrochloride showing the molecular arrangement with aromatic rings, hydroxyl groups, methoxy group, amino sugar moiety, and associated hydrochloride.*

FDA Label Image

Mpeg-dspe (1a930cb7 5363 4229 9f39 53edc07a43d6 02)

Chemical structure diagram of the active ingredient doxorubicin hydrochloride, showing molecular components including polymeric segments and lipid moieties, consistent with a liposomal formulation.*

FDA Label Image

Hspc (1a930cb7 5363 4229 9f39 53edc07a43d6 03)

Chemical structure diagram showing a phospholipid molecule with choline head group, which is part of the liposomal component in doxorubicin hydrochloride liposomal injection. The structure includes two fatty acid chains of variable length (n=14 or 16).*

FDA Label Image

Pegylated Liposome (1a930cb7 5363 4229 9f39 53edc07a43d6 04)

An illustration showing the structure of a liposomal formulation of doxorubicin hydrochloride. The diagram labels the MPEG-DSPE coating on the outer surface, the aqueous core containing entrapped doxorubicin HCl, and the liposomal bilayer surrounding the core.*

FDA Label Image

Figure 1 (1a930cb7 5363 4229 9f39 53edc07a43d6 05)

A Kaplan-Meier survival curve graph showing percent of subjects progression-free over time in months, comparing treatment with Doxorubicin HCl plus Bortezomib versus Bortezomib alone. The x-axis represents time in months up to 15, and the y-axis shows percent progression-free subjects from 0 to 100. Data points are censored as indicated. A table below lists the number of subjects at risk for each treatment group at various time points.*

FDA Label Image

Doxo 20mg/10ml 10 mL Vial Label (1a930cb7 5363 4229 9f39 53edc07a43d6 06)

Label for DOXORUBICIN HYDROCHLORIDE Liposome Injection by BluePoint Laboratories. The injection strength is 20 mg/10 mL (2 mg/mL) in a 10 mL single-dose vial. It includes storage instructions to refrigerate at 2° to 8° C and a warning about its liposomal formulation. The label states it is for intravenous infusion after dilution and includes manufacturer information for ForDoz Pharma Corporation.*

FDA Label Image

Doxo 20mg/10ml 10 mL Vial Carton (1a930cb7 5363 4229 9f39 53edc07a43d6 07)

Packaging label for DOXOrubicin Hydrochloride Liposome Injection, 20 mg/10 mL (2 mg/mL). This is a 10 mL single-dose vial label from BluePoint Laboratories, NDC 68001-629-36. The label includes dosing concentration, a warning not to substitute for doxorubicin hydrochloride, manufacturer and storage instructions, as well as a barcode.*

FDA Label Image

Doxo 50mg/25ml 10 mL Vial Label (1a930cb7 5363 4229 9f39 53edc07a43d6 08)

Label for Doxorubicin Hydrochloride Liposome Injection, 50 mg/25 mL (2 mg/mL) in a 25 mL single-dose vial. The label indicates storage between 2° to 8° C, and dilution instructions using 5% Dextrose Injection. Manufactured by ForDoz Pharma Corporation for BluePoint Laboratories, with warnings about its liposomal formulation and cytotoxic nature.*

FDA Label Image

Doxo 50mg/25ml 10 mL Vial Carton (1a930cb7 5363 4229 9f39 53edc07a43d6 09)

Packaging label for DOXOrubicin Hydrochloride Liposome Injection 50 mg/25 mL (2 mg/mL) in a 25 mL single-dose vial. The label includes dosing concentration, a warning that this liposomal formulation should not be substituted for doxorubicin hydrochloride, and manufacturer information listing ForDoz Pharma Corporation and BluePoint Laboratories. Storage and usage instructions are also partially visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.